UnitedHealth Q2: Seeing More Clarity Could Be Positive For The Stock

UnitedHealth Group (UNH) delivered a mixed Q2 FY2025 earnings report, with revenue slightly topping estimates but EPS significantly missing by 8.3% due to higher-than-expected medical costs, particularly within its Medicare Advantage portfolio. The company subsequently lowered its FY2025 adjusted EPS guidance to "at least $16 per share," implying a 42.2% YoY decline, as Medicare Advantage cost trends are now projected at 7.5% for 2025 and 10% for 2026, leading to a sharp contraction in UnitedHealthcare's operating margin. While management plans pricing increases and PPO exits to stabilize margins, a full earnings recovery is not anticipated until late FY2026 or early FY2027, prompting a market reset of expectations and a discounted forward valuation despite the ongoing DOJ investigation.

Analysis

UnitedHealth Group's Q2 FY2025 results revealed a significant deterioration in profitability, with an 8.3% miss on non-GAAP EPS despite revenues slightly exceeding consensus. The primary driver was a severe and underestimated surge in medical costs, which caused the UnitedHealthcare segment's operating margin to contract sharply to 2.4% from 6.2% in the prior quarter. Management has now reset expectations downward, guiding for FY2025 adjusted EPS of 'at least $16,' implying a 42.2% year-over-year decline and an accelerating 66.2% drop in the second half of the year. This revision is underpinned by a higher projected Medicare Advantage cost trend of 7.5% for 2025 and 10% for 2026. While the company plans to restore margins through price increases and exiting certain PPO offerings, a meaningful earnings growth inflection is not anticipated until late 2026 or early 2027. The stock's valuation now reflects this distress, trading at a forward P/E of 12.5x—a substantial 40% discount to its 5-year average—although the ongoing DOJ investigation remains a source of tail risk.

Key Decisions for Investors

• Investors should brace for continued stock volatility and further potential downward pressure in the near term, as the company projects an accelerated 66.2% YoY decline in adjusted EPS for the second half of FY2025.
• Long-term investors may consider the current valuation, which is at a 30-40% discount to sector and historical averages, as a potential entry point but must be prepared to hold through a bumpy recovery period not expected to materialize until late 2026.
• Key performance indicators to monitor are the stabilization of the UnitedHealthcare operating margin and the trade-off between membership trends and the price increases planned for 2026.
• The ongoing DOJ investigation, while presented as a tail risk, should be monitored closely as any adverse developments would create an additional headwind for the stock.